Redox metals in Alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 1012, Issue , 2004, Pages 171-178

  Todorich, Bozho M ^a   Connor, James R ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease (AD); Brain; Copper; Iron; Redox metal; Zinc

Indexed keywords

CHELATING AGENT; CLIOQUINOL; COPPER; DEFEROXAMINE; IRON; METAL DERIVATIVE; PENICILLAMINE; ZINC;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CELL FUNCTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HOMEOSTASIS; HUMAN; MULTIPLE SCLEROSIS; OXIDATION REDUCTION REACTION; PATHOGENESIS; REVIEW; TREATMENT OUTCOME;

EID: 1842504320     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1306.014     Document Type: Review

References (47)

1. CONNOR, J.R. 1997. Evidence for iron mismanagement in the brian in neurological disorders. In Metals and Oxidative Damage in Neurological Disorders, pp. 23-39. Plenum. New York.
2. HENDERSON, R.J. & J.R. CONNOR. 2003. Iron's involvement in the molecular mechanisms of Alzheimer's disease pathogenesis. In Neuronal and Vascular Plasticity: Elucidating Basic Cellular Mechanisms for Future Therapeutic Discovery. Kluwer. Dordrecht/Detroit.
3. KAUR, D. & J.K. ANDERSEN. 2002. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility? Aging Cell 1(1): 17-21.
4. BEARD, J.L. & J.R. CONNOR. 2003. Iron status and neural functioning. Annu. Rev. Nutr. 23: 41-58.
5. BENKOVIC, S. & J.R. CONNOR. 1993. Ferritin, transferrin, and iron in normal and aged rat brains. J. Comp. Neurol. 338: 97-113.
6. TOYOKUNI, S. 2002. Iron and carcinogenesis: from Fenton reaction to target genes. Redox Rep. 7(4): 189-197.
7. WAGNER, K.R., F.R. SHARP, T.D. ARDIZZONE et al. 2003. Heme and iron metabolism: role in cerebral hemorrhage. J. Cereb. Blood Flow Metab. 23(6): 629-652.
8. PINERO, D. & J.R. CONNOR. 2000. Iron in the brain: an important contributor in normal and diseased states. Neuroscientist 6(6): 435-453.
9. KAKHLON, O. & Z.I. CABANTCHIK. 2002. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radical Biol. Med. 33(8): 1037-1046.
10. THOMPSON, K., S. SHOHAM & J.R. CONNOR. 2001. Iron and neurodegenerative disorders. Brain Res. Bull. 55(2): 155-164.
11. BOUTON, C. & J.C. DRAPIER. 2003. Iron regulatory proteins as NO signal transducers. Sci. STKE 182: 17.
12. PINERO, D.J., J. HU & J.R. CONNOR. 2000. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. Cell. Mol. Biol. 46(4): 761-776.
13. ANDREWS, N. 1999. The iron transporter DMTI. Int. J. Bjochem. Cell Biol. 31(10): 991-994.
14. BURDO, J.R., S.L. MENZIES, I.A. SIMPSON et al. 2001. Distribution of divalent metal transporter I and metal transport protein 1 in the normal and Belgrade rat. J. Neurosci. Res. 66: 1198-1207.
15. BURDO, J.R., J. MARTIN, S.L. MENZIES et al. 1999. Cellular distribution of iron in the brain of the Belgrade rat. Neuroscience 93(3): 1189-1196.
16. FAILLA, M. 2003. Trace elements and host defense: recent advances and continuing challenges. J. Nutr. 133: 1443S-1447S.
17. BUSH, A.I. 2002. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging 23(6): 1031-1038.
18. BEARD, J.L. & J.R. CONNOR. 2003. Iron status and neural functioning. Annu. Rev. Nutr. 23: 41-58.
19. CONNOR, J.R., E.A. MILWARD, S. MOALEM et al. 2001. Is hemochromatosis a risk factor for Alzheimer's disease? J. Alzheimer's Dis. 3(5): 471-477.
20. SMITH, M.A., L.R. PEGGY, L.M. HARRIS et al. 1997. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94: 9866-9868.
21. FINEFROCK, A.E., A.I. BUSH & P.M. DORAISWAMY. 2003. Current status of metals as therapeutic targets in Alzheimer's disease. J. Am. Geriatr. Soc. 51(8): 1143-1148.
22. ATWOOD, C.S., X. HUANG & R.D. MOIR, 1999. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. In Metal Ions in Biological Systems, pp. 309-364. Dekker, New York.
23. ROGERS, J.T., J.D. RANDALL, C.M. CAHILL et al. 2002. An iron-responsive element type 11 in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript J. Biol. Chem. 277: 45518-45528.
24. MARTIN, W.R., F.Q. YE & P.S. ALLEN. 1998. Increasing striatal iron content associated with normal aging. Mov. Disord. 13(2): 281-286.
25. BARTZOKIS, G., M. BECKSON, D.B. HANCE et al. 1997. NMR evaluation of age-related increase of brain iron in young adult and older normal males. Magn. Reson. Imaging 15(1): 29-35.
26. CONNOR, J.R., B.S. SNYDER, P. AROSIO et al. 1995. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65: 717-724.
27. MATTSON, M., W.A. PEDERSEN, W. DUAN et al. 1999, Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's disease. Ann. N.Y. Acad. Sci. 893: 154-175.
28. SAMPIETRO, M., L. CAPUTO, A. CASATTA et al. 2001. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol. Aging 22(4): 563-568.
29. HANSON, E.H., G. IMPERATORE & W. BURKE. 2001. HFE gene and hereditary hemochromatosis: a HuGE review. Am. J. Epidemiol. 154: 193-206.
30. MOALEM, S., M.E. PERCY, D.F. ANDREWS et al. 2000. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am. J. Med. Genet. 93: 58-66.
31. CHAMMERMEYER, J. 1947. Deposition of iron in the paraventricular areas of the human brain in hemochromatosis. J. Neuropathol. Exp. Neurol. 6: 111-127.
32. SHELDON, J.H. 1935. Hemochromatosis, pp. 155-159. Oxford University Press. London/New York.
33. STREMMEL, W., H.D. RIEDEL, C. NIEDERAU & G. STROHMEYER. 1993. Pathogenesis of genetic hemochromatosis. Eur. J. Clin. Invest. 23: 321.
34. BASTIN, J.M., M. JONES, C.A. O'CALLAGHAN et al. 1998. Kupffer cell staining by an HFE-specific monoclonal antibody: implications for hereditary haemochromatosis. Br. J. Haematol. 103(4): 931-941.
35. COMBARROS, O., M. GARCIA-ROMAN, A. FONTALBA et al. 2003. Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease. Dement. Geriatr. Cognit Disord. 15(3): 151-154.
36. PULLIAM, J.F., C.D. JENNINGS, R.J. KRYSCIO et al. 2003. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am. J. Med. Genet. 119B(1): 48-53.
37. NAMEKATA, K., M. IMAGAWA, A. TERASHI et al. 1997. Association of transform C2 allele with late-onset Alzheimer's disease. Hum. Genet. 101(2): 126-129.
38. HUANG, X., C.S. ATWOOD & M.A. HARTSHORN. 1999. The peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616.
39. PHINNEY, A.L., B. DRISALDI, S.D. SCHMIDT et al. 2003. In vivo reduction of amyloid-{beta} by a mutant copper transporter. Proc. Natl. Acad. Sci. USA. In press.
40. BAYER, T.A., S. SCHAFER, A. SIMONS et al. 2003. Dietary Cu stabilizes brain superoxide dismutase-1 activity and reduces amyloid Aβ production in APP23 transgenic mice. Proc. Natl. Acad. Sci. USA. In press.
41. SPARKS, D.L. & B.G. SCHREURS. 2003. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 100(19): 11065-11069.
42. ROSSI, L., M.R. CIRIOLO, E. MARCHESE et al. 1994. Differential decrease of copper content and of copper binding to superoxide dismutase in liver, heart, and brain of copper-deficient rats. Biochem. Biophys. Res. Commun. 203: 1028-1034.
43. ROSSI, L., R. SQUITTI, P. PASQUALETTI et al. 2002. Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine. Neurosci. Lett. 329(2): 137-140.
44. EL-YOUSSEF, M. 2003. Wilson disease. Mayo Clin. Proc. 78(9): 1126-1136.
45. LEE, J.Y., T.B. COLE, R.D. PALMITER et al. 2002. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. USA 99(11): 7705-7710.
46. MALECKI, E.A. & J.R. CONNOR. 2002. The case for iron chelation and/ or antioxidant therapy in Alzheimer's disease. Drug Dev. Res. 56: 526-530.
47. CRAPPER MCLACHLAN, D.R., A.J. DALTON, T.P.A. KRUK et al. 1991. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337: 1304-1308.